All In Biotech

Drug Trial Radar · NCT04254978

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Sep 8, 2020

Primary completion

Mar 23, 2023

Study completion Mar 23, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: * The safety and tolerability of Bomedemstat * The pharmacodynamic effect of Bomedemstat

Conditions

  • Essential Thrombocythemia

Interventions

  • BomedemstatDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 30 months
  2. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 28 months
  3. Percentage of Participants With Platelet Count ≤400 k/μL at Day 169Time frame: Up to day 169

Locations

26 sites in 7 countries. Site status is shown where the registry gives one.

  • Local Institution

    Jacksonville, Florida

  • Local Institution

    Ann Arbor, Michigan

  • Local Institution

    New York, New York

  • Local Institution

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Local Institution

    Pittsburgh, Pennsylvania

  • Local Institution

    Seattle, Washington

  • Local Institution

    Herston, Brisbane, Australia

  • Local Institution

    Camperdown, New South Wales, Australia

  • Local Institution

    St Leonards, New South Wales, Australia

  • Local Institution

    Southport, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Local Institution

    Clayton, Victoria, Australia

  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ)

    Essen, Germany

  • Local Institution

    Jena, Germany

  • Local Institution

    Hong Kong, Hong Kong

  • Local Institution

    Alessandria, Italy

  • Local Institution

    Bologna, Italy

  • CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi

    Florence, Italy

  • Local Institution

    Varese, Italy

  • Local Institution

    Auckland, New Zealand

  • Middlemore Hospital

    Auckland, New Zealand

  • Local Institution

    London, United Kingdom

  • Guys and St Thomas Hospital

    London, United Kingdom

  • Local Institution

    London, United Kingdom

  • Local Institution

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.